Follow‑Up Assessment and Management of Obsessive‑Compulsive Disorder

Severity Assessment with the Y‑BOCS

Administer the Yale‑Brown Obsessive‑Compulsive Scale at every follow‑up visit to track symptom trajectory; the 10‑item clinician‑rated instrument yields a total score from 0‑40. 1
Separate scoring of obsessions (items 1‑5) and compulsions (items 6‑10) is recommended; a subscale score ≥ 14 indicates severe OCD even when only one symptom type is present. 4
Be aware that avoidance of triggering situations can artificially lower Y‑BOCS scores; explicitly inquire about avoided contexts to obtain an accurate severity estimate. 1

Document the primary symptom dimension(s) (contamination/cleaning, harm/checking, symmetry/ordering, or unacceptable/taboo thoughts) because dimension guides exposure planning. 6
Assess insight using DSM‑5 specifiers: good/fair (beliefs probably untrue), poor (beliefs probably true), or absent/delusional (beliefs completely true). 4
When insight is absent or delusional, augment SSRI + ERP with an atypical antipsychotic. 7

Systematically screen for anxiety disorders, major depressive disorder, impulse‑control disorders, substance‑use disorders, and tic disorders; approximately 90 % of individuals with OCD meet criteria for at least one additional lifetime psychiatric disorder. 6
Differentiate ADHD inattention (ego‑syntonic, not anxiety‑driven) from OCD compulsions (ego‑dystonic rituals aimed at neutralizing obsessions). 2
Recognize sexual‑orientation obsessions as intrusive, ego‑dystonic thoughts rather than identity crises or paraphilias. 1

Screen for active suicidal ideation at every visit; OCD is associated with an elevated risk of mortality. 6
If suicidal ideation is present, evaluate for psychotic features (e.g., auditory hallucinations, paranoia) that would warrant immediate hospitalization and antipsychotic augmentation. 7
Do not rely on “no‑suicide contracts,” as their protective effect is unproven. 7

Verify adherence to an SSRI and confirm the patient has received the maximum tolerated dose for at least 8–12 weeks before labeling treatment as a failure. 7
Counsel about common SSRI adverse effects (gastrointestinal upset, sexual dysfunction, activation/insomnia, weight change, emotional blunting). 7
Use OCD‑specific dosing (e.g., sertraline 150‑200 mg/day, fluoxetine 40‑80 mg/day); depression‑level doses are insufficient for OCD. 7
When an atypical antipsychotic is added, monitor metabolic parameters (weight, glucose, lipids) and extrapyramidal symptoms. 7

Confirm active participation in ERP (the gold‑standard psychotherapy for OCD) by asking about session frequency and homework completion. 2
Inquire about specific exposure exercises performed between sessions and whether the patient resists compulsions during those exposures. 7
Identify barriers to ERP adherence (limited therapist availability, cost, transportation, fear of exposures, misunderstanding of ERP rationale). 7
For patients not currently in ERP, provide psycho‑education that combined SSRI + ERP yields superior outcomes compared with medication alone and arrange referral to an OCD‑specialized therapist. 2

Measure impairment in occupational/academic, social, and family/intimate domains using the Sheehan Disability Scale or a comparable tool. 6
Severe OCD is linked to an average of ~45 days out of role per year; ask about days missed from work or school in the past month. 6
Assess family accommodation behaviors (family members participating in rituals, providing reassurance, or modifying routines), as these maintain symptoms and predict poorer prognosis. 3

Early age at onset (< 18 years) predicts a worse long‑term outcome and a higher likelihood of comorbid tic disorders. 6
For patients achieving remission (Y‑BOCS ≤ 8), continue full‑dose treatment for 12‑24 months before considering taper, given the high risk of relapse. 7
Define treatment‑resistant OCD as failure to respond to three adequate SSRI trials (including clomipramine), two augmentation strategies, and ≥ 20 hours of ERP over 5 years with a Y‑BOCS ≥ 28. 4

Do not mistake compulsions for ADHD impulsivity; compulsions are anxiety‑driven rituals, whereas ADHD impulsivity is ego‑syntonic and not ritualistic. 2
Do not declare SSRI failure before an 8‑12‑week trial at the maximum tolerated dose, as OCD requires higher doses and longer treatment durations than depression. 7